J. Gonza´lez-Sab´ın et al. / Tetrahedron: Asymmetry 17 (2006) 449–454
453
(CH), 67.43 (CH2), 67.54 (CH), 121.94 (CH), 125.75
(CH), 137.11 (CH), 147.96 (CH), 150.39 (C), 164.18
(C@O). MS (ESI+) m/z (rel. intensity): 290.1 [(M+H)+,
100], 312.1 [(M+Na)+, 25], 328.1 [(M+K)+, 10].
22.30 (CH2), 23.61 (CH2), 24.33 (CH2), 24.59 (CH2),
32.01 (CH2), 47.13 (CH2), 52.29 (CH), 61.68 (CH),
125.27 (CH), 128.43 (CH), 129.66 (CH), 135.11 (C),
166.77 (C@O). MS (ESI+) m/z (rel. intensity): 467.5
[(M+H)+, 100].
4.5. Synthesis of bisaminoamides. General procedure
4.5.5. (10R,100R,20R,200R)-N,N0-Bis-[2-(morpholin-4-yl)-
To a solution of diamine (1R,2R)-2a–d (0.26 mmol) in
dichloromethane (5.0 mL), the corresponding acid
dichloride (0.13 mmol) was added under a nitrogen
atmosphere. After stirring to room temperature for
4 h, the solvent was evaporated and the resulting crude
purified by flash chromatography (mixtures of hexane–
ethyl acetate).
cyclohexyl]pyridine-2,6-dicarboxamide 8a. Yield: 93%;
20
mp 110–112 ꢁC; ½aꢁD ¼ ꢀ167:0 (c 0.60, CHCl3), >99%
ee; IR (neat) 3453, 3354, 1663 cmꢀ1
;
1H NMR
(300 MHz): d 1.05–1.45 (m, 8H), 1.65–2.00 (m, 6H),
2.25–2.75 (m, 12H), 3.45–3.85 (m, 10H), 8.01 (t, 1H,
J = 7.8 Hz), 8.21 (d, 2H, NH, J = 5.7 Hz), 8.32 (d, 2H,
J = 8.0 Hz); 13C NMR (75.5 MHz): d 23.44 (CH2),
24.39 (CH2), 25.30 (CH2), 32.82 (CH2), 48.33 (CH2),
50.16 (CH), 67.39 (CH2), 67.64 (CH2), 124.40 (CH),
138.62 (CH), 148.91 (C), 163.48 (C@O). MS (EI+) m/z
(rel. intensity): 499.5 (M+, 32), 469.5 (26), 167.1 (90).
4.5.1. (10R,100R,20R,200R)-N,N0-Bis-[2-(morpholin-4-yl)-
cyclohexyl]benzene-1,5-dicarboxamide 7a. Yield: 95%;
20
mp 85–87 ꢁC; ½aꢁD ¼ ꢀ98:9 (c 0.67, CHCl3), >99% ee;
1
IR (neat) 3462, 3322, 1643 cmꢀ1; H NMR (300 MHz):
d 1.10–1.35 (m, 8H), 1.65–2.05 (m, 6H), 2.35–2.75 (m,
12H), 3.45–3.80 (m, 10H), 7.06 (br s, 2H, NH), 7.49 (t,
1H, J = 7.7 Hz), 7.89 (d, 2H, J = 7.7 Hz), 8.28 (s, 1H);
13C NMR (75.5 MHz): d 23.13 (CH2), 24.51 (CH2),
25.26 (CH2), 32.62 (CH2), 48.17 (CH2), 50.47 (CH),
67.33 (CH2+CH), 125.44 (CH), 128.72 (CH), 129.44
(CH), 135.22 (C), 166.65 (C@O). MS (EI+) m/z (rel.
intensity): 498.5 [M+, 37], 468.5 (33), 167.1 (100).
4.5.6. (10R,100R,20R,200R)-N,N0-Bis-{2-[isopropyl(methyl)-
amino]cyclohexyl}pyridine-2,6-dicarboxamide 8b. Yield:
20
93%; mp 116–118 ꢁC; ½aꢁD ¼ ꢀ183:8 (c 0.93, CHCl3),
1
>99% ee; IR (neat) 3442, 3396, 1666 cmꢀ1; H NMR
(300 MHz): d 0.90–1.50 (m, 20H), 1.60–1.95 (m, 6H),
2.22 (m, 6H), 2.45–2.70 (m, 4H), 2.93 (hept, 2H,
J = 6.3 Hz), 3.79 (m, 2H), 7.97 (t, 1H, J = 7.8 Hz), 8.15
(br s, 2H, NH), 8.31 (d, 2H, J = 7.8 Hz); 13C NMR
(75.5 MHz): d 20.81 (CH3), 21.60 (CH3), 24.68 (CH2),
25.71 (CH2), 26.60 (CH2), 31.14 (CH3), 33.01 (CH2),
51.02 (CH), 51.08 (CH), 51.17 (CH), 64.30 (CH),
124.28 (CH), 138.39 (CH), 149.14 (C), 163.46 (C@O).
MS (EI+) m/z (rel. intensity): 471.5 (M+, 17), 428.5 (100).
4.5.2. (10R,100R,20R,200R)-N,N0-Bis-{2-[isopropyl(methyl)-
amino]cyclohexyl}benzene-1,5-dicarboxamide 7b. Yield:
20
95%; mp 80–82 ꢁC; ½aꢁD ¼ ꢀ111:1 (c 0.50, CHCl3),
>99% ee; IR (neat) 3358, 1642 cmꢀ1
;
1H NMR
(300 MHz): d 0.90–1.55 (m, 20H), 1.65–2.00 (m, 6H),
2.23 (s, 6H), 2.55–2.80 (m, 4H), 2.98 (hept, 2H,
J = 6.3 Hz), 3.70 (m, 2H), 7.49 (t+br s, 1H+2NH,
J = 7.8 Hz), 7.90 (dd, 2H, J = 7.8 and 1.6 Hz), 8.30 (s,
1H); 13C NMR (75.5 MHz): d 20.39 (CH3), 21.31
(CH3), 24.52 (CH2), 25.58 (CH2), 31.13 (CH3), 32.50
(CH2), 51.29 (CH), 51.41 (CH), 64.38 (CH), 125.47
(CH), 128.49 (CH), 129.74 (CH), 135.11 (C), 166.78
(C@O). MS (ESI+) m/z (rel. intensity): 471.5
[(M+H)+, 30].
4.5.7. (10R,100R,20R,200R)-N,N0-Bis-[2-(piperidin-1-yl)cyclo-
hexyl]pyridine-2,6-dicarboxamide 8c. Yield: 90%; mp
20
79–81 ꢁC; ½aꢁD ¼ ꢀ186:9 (c 0.50, CHCl3), >99% ee; IR
1
(neat) 3472, 3349, 1668 cmꢀ1; H NMR (300 MHz): d
1.05–1.60 (m, 20H), 1.65–2.00 (m, 5H), 2.20–2.70 (m,
13H), 3.68 (m, 2H), 8.01 (t, 1H, J = 7.8 Hz), 8.34 (d,
2H, J = 7.8 Hz), 8.57 (d, 2H, NH, J = 3.9 Hz); 13C
NMR (75.5 MHz): d 23.46 (CH2), 24.55 (CH2), 24.79
(CH2), 25.66 (CH2), 27.04 (CH2), 32.67 (CH2), 49.29
(CH2), 51.04 (CH), 67.90 (CH), 124.11 (CH), 138.53
(CH), 149.02 (C), 165.73 (C@O). MS (ESI+) m/z (rel.
intensity): 496.5 [(M+H)+, 100], 518.5 [(M+Na)+, 20].
4.5.3. (10R,100R,20R,200R)-N,N0-Bis-[2-(piperidin-1-yl)cyclo-
hexyl]benzene-1,5-dicarboxamide 7c. Yield: 94%; mp
20
177–179 ꢁC; ½aꢁD ¼ ꢀ130:7 (c 0.50, CHCl3), >99% ee;
IR (neat) 3333, 1644 cmꢀ1
,
1H NMR (300 MHz): d
4.5.8. (10R,100R,20R,200R)-N,N0-Bis-[2-(pyrrolidin-1-yl)-
1.05–2.00 (m, 26H), 2.10–2.75 (m, 12H), 3.66 (m, 2H),
7.28 (br s, 2H, NH), 7.53 (t, 1H, J = 7.8 Hz), 7.94 (d,
2H, J = 7.8 Hz), 8.27 (s, 1H); 13C NMR (75.5 MHz): d
23.01 (CH2), 24.49 (CH2), 24.72 (CH2), 25.51 (CH2),
26.73 (CH2), 32.40 (CH2), 49.11 (CH2), 51.08 (CH),
67.73 (CH), 125.29 (CH), 128.61 (CH), 129.40 (CH),
135.37 (C), 166.92 (C@O). MS (ESI+) m/z (rel. inten-
sity): 495.5 [(M+H)+, 100].
cyclohexyl]pyridine-2,6-dicarboxamide 8d. Yield: 90%;
20
mp 94–96 ꢁC; ½aꢁD ¼ ꢀ117:8 (c 0.50, CHCl3), >99% ee;
IR (neat) 3471, 3339, 1666 cmꢀ1
;
1H NMR
(300 MHz): d 1.00–1.90 (m, 22H), 2.40–2.65 (m, 12H),
3.70–3.90 (m, 2H), 7.98 (t, 1H, J = 7.7 Hz), 8.30 (d+br
s, 2H+2NH, J = 7.7 Hz); 13C NMR (75.5 MHz): d
23.10 (CH2), 23.81 (CH2), 24.09 (CH2), 24.42 (CH2),
31.61 (CH2), 47.60 (CH2), 51.68 (CH), 62.09 (CH),
124.33 (CH), 138.59 (CH), 149.01 (C), 163.28 (C@O).
MS (ESI+) m/z (rel. intensity): 468.5 [(M+H)+, 100].
4.5.4. (10R,100R,20R,200R)-N,N0-Bis-[2-(pyrrolidin-1-yl)-
cyclohexyl]benzene-1,5-dicarboxamide 7d. Yield: 95%;
20
mp 120–122 ꢁC; ½aꢁD ¼ ꢀ84:9 (c 0.50, CHCl3), >99%
4.6. Addition of diethylzinc to aldehydes. General
procedure
ee; IR (neat) 3317, 1643 cmꢀ1; H NMR (300 MHz): d
1
1.05–2.00 (m, 22H), 2.10–2.75 (m, 12H), 3.66 (m, 2H),
7.15 (br s, 2H, NH), 7.45 (t, 1H, J = 7.8 Hz), 7.85 (d,
2H, J = 8.0 Hz), 8.36 (s, 1H); 13C NMR (75.5 MHz): d
To a solution of the optically active ligand (0.10 mmol)
in toluene (1.8 mL), diethylzinc (3.2 mmol, 3.2 mL of a